E
Exin Therapeutics
AI-driven genetic therapies targeting neural circuit imbalances
About Exin Therapeutics
Exin Therapeutics is a biotechnology company founded in 2024 by a team of three Oxford-educated neuroscientists: Gabriel Ocana Santero, Ivan Lazarte, and Marko Tvrdic. The company, headquartered in San Francisco, operates as a participant in the Y Combinator Winter 2025 batch. The founding team combines extensive experience in neuroscience, gene therapy, biochemistry, and physics. Ivan Lazarte's personal motivation stems from his brother's experience with Autism Spectrum Disorder (ASD), driving the company's mission to improve the quality of life for patients with neurological conditions.
The firm is developing a platform for creating precision genetic therapies aimed at neurological and neuropsychiatric disorders by addressing them from a circuit-level perspective. Rather than focusing on correcting missing genes, Exin's approach involves supplementing existing genes to modify neural activity and correct imbalances between excitatory and inhibitory signals in brain circuits. This method is designed to be independent of a patient's specific genetic background. The company's initial focus is on conditions such as epilepsies associated with autism, Parkinson's disease, and debilitating symptoms of ASD.
A core component of Exin's strategy is its multimodal AI drug discovery platform. This platform utilizes machine learning to analyze high-density, in-house generated data from high-throughput mouse studies, including neural activity, behavior, and transcriptomics. The AI models identify disease drivers and predict the therapeutic potential of drug candidates, streamlining the preclinical R&D process and prioritizing the most promising assets for testing. This AI-guided approach aims to accelerate the traditionally slow process of developing drugs for brain disorders. The company has raised $500K in a seed funding round and is backed by investors including Y Combinator, 468 Capital, Multimodal Ventures, Tekedia Capital, and Theory Forge Ventures.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 7
- Open positions
- 1
- Dealroom signal
- 70.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Neurology, Genetics and genomics, Precision Medicine, Gene Therapy, Brain Computer Interfaces, AI Drug Discovery, YC W25, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2025 | $125K | $500K | Y Combinator | — |
Growth signals
Latest recorded traffic for Exin Therapeutics is 1K monthly website visits, up 0% over the last three months. Exin Therapeutics's team grew 133.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Exin Therapeutics in the San Francisco ecosystem
The Exin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exin Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










